National Institute of Neurological Disorders and Stroke (NINDS)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Institute of Neurological Disorders and Stroke (NINDS) sits in the top decile of US sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count).

567 total trials 48 currently recruiting 467 completed early-phase tilt top decile by trial count

National Institute of Neurological Disorders and Stroke (NINDS): 567 sponsored US clinical trials, 48 recruiting.

National Institute of Neurological Disorders and Stroke (NINDS) sponsors 567 registered US clinical trials on ClinicalTrials.gov, 48 of them currently recruiting, and 467 completed. 16 of these trials are in Phase 3-4 (later-stage) and 158 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 23 trials.

Top-decile sponsor footprint

National Institute of Neurological Disorders and Stroke (NINDS) ranks in the top decile of sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 70/100

467 of 508 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

567 total, page 7 of 12

COMPLETED

Brain Activity in Visual-Motor Behavior

NCT00077038

COMPLETED Phase 1

Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

NCT00076843

COMPLETED

Study of Brain Function During Cognitive Tasks

NCT00076739

COMPLETED Phase 1

Phase 1 Trial of Idebenone to Treat Patients With Friedreich's Ataxia

NCT00078481

COMPLETED Phase 1

Direct Current Brain Polarization in Frontotemporal Dementia

NCT00077896

COMPLETED

Brain Control of Movements in Cerebral Palsy

NCT00076596

COMPLETED

Brain Changes Associated With Learning a Motor Task

NCT00076466

COMPLETED Phase 2

Levetiracetam Treatment of L-dopa Induced Dyskinesias

NCT00076674

COMPLETED

Enhanced Tactile Memory in the Blind

NCT00076700

COMPLETED Phase 2

Alternative Dosing and Regimen of Replagal to Treat Fabry Disease

NCT00075244

COMPLETED

Role of the Right Brain in Recovery of Language Function in Chronic Stroke

NCT00076479

COMPLETED

Spinal Reflexes in Motor Skill Learning

NCT00076583

COMPLETED

Relationship Between Sensory and Motor Systems in Restless Leg Syndrome

NCT00074672

COMPLETED

Spinal Cord Plasticity

NCT00073606

COMPLETED Phase 4

Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors

NCT00075166

COMPLETED

Role of the Brain in Processing Visually Presented Objects

NCT00357695

COMPLETED

MRI in Autosomal Dominant Partial Epilepsy With Auditory Features

NCT00072813

COMPLETED Phase 1

Improvement of Use Dependent Plasticity in Chronic Stroke Patients

NCT00072735

COMPLETED

Classification of Cerebral Palsy Subtypes

NCT00072800

COMPLETED

The Physiology of Tricks

NCT00072956

COMPLETED Phase 2

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

NCT00071838

COMPLETED

Non-Invasive Seizure Localization in Patients With Medically Refractory Localization Related Epilepsy: Synchronized MEG-EEG Recordings

NCT00071305

COMPLETED

Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor-Associated Vasculature in Patients With Metastatic Breast Cancer

NCT00071357

COMPLETED Phase 2

An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease

NCT00071877

COMPLETED

Brain Function in Primary Lateral Sclerosis

NCT00071435

COMPLETED

Analysis of Brain Metastasis in Patients With Lung Cancer

NCT00071344

COMPLETED Phase 1

An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease

NCT00357786

COMPLETED

Brain Activation During Simple Vocal Behaviors

NCT00071734

COMPLETED

Activating Effects of Sleep Deprivation on Synchronized MEG-EEG Recordings of Epilepsy Patients With Non-Diagnostic EEG

NCT00071370

COMPLETED

Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2

NCT00071383

COMPLETED

Evaluation of Chronic Orthostatic Intolerance

NCT00069693

COMPLETED

Improving Motor Learning in Stroke Patients

NCT00067197

COMPLETED Phase 2

Reducing Seizure Frequency Using Cooling of the Head and Neck

NCT00067210

COMPLETED

The Effect of Dopamine on Motor Skills Training

NCT00067275

COMPLETED

Studying Use-Dependent Plasticity

NCT00067223

COMPLETED

Brain Mapping of Voice Control

NCT00066911

COMPLETED

Light Scattering Spectroscopy to Determine Brain Tumors

NCT00067418

COMPLETED

Investigating Endothelial Precursor Cells (EPCs)

NCT00067067

TERMINATED Phase 3

Modafinil to Treat Fatigue in Post-Polio Syndrome

NCT00067496

COMPLETED

Evaluating the Remote Effects of Stroke With MRI and PET Scans

NCT00063180

COMPLETED Phase 1

Investigating the Safety of srTMS in the Treatment of Parkinson's Disease

NCT00063284

COMPLETED

Using fMRI to Understand the Roles of Brain Areas for Fine Hand Movements

NCT00063115

COMPLETED

Studying Automatic Movements in Patients With Parkinson's Disease

NCT00063661

COMPLETED

Stimulating Deep Brain Regions With a Magnetic Stimulator

NCT00063245

COMPLETED

Measuring Levels of SMN in Blood Samples of SMA Patients

NCT00061607

COMPLETED

Investigating the Cognitive Processes That Underlie Social Knowledge and Behavior

NCT00061334

COMPLETED Phase 2

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

NCT00061373

COMPLETED Phase 4

Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance

NCT00060866

COMPLETED

Magnetic Resonance Imaging of Calculus Problem Solving

NCT00060658

COMPLETED

MRI Study of Self-Perception of Postural Stability

NCT00060593

← Previous Page 7 of 12 Next →

Phase Distribution

PhaseTrial count
Phase 1 80
Phase 2 78
Phase 3 11
Phase 4 5

What is open in the National Institute of Neurological Disorders and Stroke (NINDS) pipeline

48 recruiting of 567 indexed (8% open); 467 completed (82%).

Phase mix: 16 late (III/IV) vs 158 early (I/II) (early-phase heavy).

Top condition: Healthy (23 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

National Institute of Neurological Disorders and Stroke (NINDS): open-pipeline peers nationwide

Peers matched on 567 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

National Institute of Neurological Disorders and Stroke (NINDS) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600 5%10%15%20%25% Total trials Recruiting share National Institute of Neurological Disorders and Stroke (NINDS)Children's Hospital Medical Center, CincinnatiUniversity of Maryland, BaltimoreAmgenMerck Sharp & DohmeNational Jewish HealthACADIA PharmaceuticalsTexas Tech University Health Sciences Center, El PasoBoehringer Ingelheim
National Institute of Neurological Disorders and Stroke (NINDS) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

National Institute of Neurological Disorders and Stroke (NINDS) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 567 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

What to do with this National Institute of Neurological Disorders and Stroke (NINDS) page

567 registered trials is a research-attention snapshot, not an endorsement of National Institute of Neurological Disorders and Stroke (NINDS) or any single study.

  • 48 of National Institute of Neurological Disorders and Stroke (NINDS)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition National Institute of Neurological Disorders and Stroke (NINDS) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Neurological Disorders and Stroke (NINDS) pipeline card: 567 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.